IN8BIO INC (INAB) Stock News

NASDAQ:INAB - Nasdaq - US45674E1091 - Common Stock - Currency: USD

2.41 -0.05 (-2.03%)

After market: 2.3508 -0.06 (-2.46%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

INAB Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Benzinga - Mentions: CDXS SLRX WVE ADIL ...

12 Health Care Stocks Moving In Thursday's After-Market Session

2 months ago - By: IN8bio, Inc

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

10 months ago - By: IN8bio, Inc

IN8bio Announces Pricing of $12.4 Million Private Placement

2 months ago - By: Benzinga - Mentions: CERO GHM SPY MPAA ...

US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market'

2 months ago - By: IN8bio, Inc

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

3 months ago - By: IN8bio, Inc

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

4 months ago - By: IN8bio, Inc

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

4 months ago - By: IN8bio, Inc

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

5 months ago - By: IN8bio, Inc

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

5 months ago - By: IN8bio, Inc

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

5 months ago - By: IN8bio, Inc

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

5 months ago - By: IN8bio, Inc

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

8 months ago - By: IN8bio, Inc

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

8 months ago - By: IN8bio, Inc

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

8 months ago - By: IN8bio, Inc

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

8 months ago - By: IN8bio, Inc

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

9 months ago - By: IN8bio, Inc

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

a year ago - By: IN8bio, Inc

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia